CeleCor Therapeutics, Zalunfiban, Disaggpro, STEMI, Heart Attack, Acute Myocardial Infarction, Cardiovascular Disease, FDA, NDA, PDUFA, Phase 3 Clinical Trial

Del Mar, California, U.S., September 30, 2026 CeleCor Therapeutics announced that the U.S. Food and Drug Administration (FDA) has...